BioPharmSignal logoBioPharmSignal

Biotech News

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

Syndax Pharmaceuticals (SNDX)Syndax PharmaceuticalsFinancing

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax”) (NASDAQ: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, has entered into privately negotiated subscription agreements for the issuance of $250.0 million aggregate

Related news

SNDXSyndax Pharmaceuticals2026-10-15 20:01 EST

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

IRONDisc Medicine2026-10-21 00:52 EST

Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

IRONDisc Medicine2026-10-19 20:01 EST

Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants

BMEABiomea Fusion2026-09-23 11:04 EST

Biomea Fusion Announces Termination of Proposed Public Offering of Securities

BMEABiomea Fusion2026-09-22 20:05 EST

Biomea Fusion Announces Proposed Public Offering of Securities

KURAKura Oncology2026-09-09 11:00 EST

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

SNDXSyndax Pharmaceuticals2026-09-01 11:00 EST

Syndax Announces Participation in September Investor Conferences

TEVATeva Pharmaceutical Industries2026-09-07 07:53 EST

Teva Announces Launch of Offering of Senior Notes

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

FATEFate Therapeutics2026-10-12 11:00 EST

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

View all latest news

Syndax Pharmaceuticals

Commercial Oncology Portfolio Syndax Pharmaceuticals develops and commercializes therapies for genetically defined leukemias and immune-mediated complications of transplantation. Its commercial portfolio is built around Revuforj and Niktimvo. Revuforj Revuforj, or revumenib, is a menin inhibitor used in acute leukemias with susceptible...

Recent company news

SNDXSyndax Pharmaceuticals2026-10-15 20:01 EST

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

SNDXSyndax Pharmaceuticals2026-10-12 20:01 EST

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

SNDXSyndax Pharmaceuticals2026-09-01 11:00 EST

Syndax Announces Participation in September Investor Conferences

SNDXSyndax Pharmaceuticals2026-08-04 20:01 EST

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

Stock data

Close
13.15 USD
Market cap
1.63B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States